Here's What I'll Be Looking for in Moderna's Earnings Report Next Week

Moderna (NASDAQ:MRNA) has spent the past two months producing and shipping its much-awaited coronavirus vaccine. But we won't see too much of an impact from its vaccine successes in its fourth-quarter and full-year earnings report. That's because Moderna began distribution only a couple of weeks before the end of that reporting period. The biotech company in a Jan. 4 update said it had at that point delivered 18 million doses to the U.S. government. At a price of $15 a dose, that represents $270 million in sales. That's only a small portion of the billions of dollars in sales expected over a full quarter.